Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Real-time Quote. Real-time Tradegate - 05/06 11:17:50 am
65.415 EUR   +1.61%
05/02 UCB FIRST THREE :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : shareholder meeting today
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Deutsche Boerse Ag
04/29/2016 05/02/2016 05/03/2016 05/04/2016 05/05/2016 Date
65.58(c) 65.075(c) 66.041(c) 65.912(c) 64.38(c) Last
300 420 0 0 0 Volume
-2.69% -0.77% +1.48% -0.20% -2.32% Change
More quotes
Financials (€)
Sales 2016 4 048 M
EBIT 2016 721 M
Net income 2016 450 M
Debt 2016 1 026 M
Yield 2016 1,92%
Sales 2017 4 281 M
EBIT 2017 875 M
Net income 2017 548 M
Debt 2017 676 M
Yield 2017 2,00%
P/E ratio 2016 25,55
P/E ratio 2017 20,70
EV / Sales 2016 3,38x
EV / Sales 2017 3,11x
Capitalization 12 637 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
05/05 | 02:00pmPresentation
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
05/02 UCB FIRST THREE MONTHS INTERIM REPOR :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
04/28 UCB : shareholder meeting today
04/25 UCB FIRST THREE MONTHS INTERIM REPOR :
04/21 UCB : Patent Issued for Protein Purification (USPTO 9309280)
04/21 UCB : Patent Issued for Chiral Intermediate, Process for Producing the Same and ..
04/14 UCB : Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab Wit..
More news
Sector news : Pharmaceuticals - NEC
10:03a DAIICHI SANKYO : awarded damages over cover-up at Indian ex-subsidiary
09:17a Cell Source Improving Immunotherapy with T-Cell Twist
08:49aDJSanofi Pressures Biotech Company On Bid -- WSJ
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions